Pulmonary Complications of Cancer Therapy
https://doi.org/10.35401/2541-9897-2024-9-4-136-144
Abstract
Currently, the literature has limited information on potential risks of pulmonary toxicity in patients receiving anticancer therapy. Nevertheless, this complication is not uncommon in some patients and can manifest in various patterns of changes in the lung parenchyma.
About the Authors
E. I. Zyablova
Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Kuban State Medical University
Russian Federation
Russian Federation
Elena I. Zyablova - Dr. Sci. (Med.), Associate Professor, Head of the Diagnostic Radiology Department No. 2, Kuban State Medical University; Head of the Radiology Unit, Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Chief Nonstaff Radiologist of the Ministry of Health of the Krasnodar Region.
ulitsa Rossiyskaya 140, Krasnodar, 350086
E. Yu. Krivitskaya
Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Kuban State Medical University
Russian Federation
Russian Federation
Elena Yu. Krivitskaya - Assistant Professor at the Diagnostic Radiology Department No. 2, Kuban State Medical University; Radiologist, Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1.
Krasnodar
I. G. Voronova
Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Kuban State Medical University
Russian Federation
Russian Federation
Irina G. Voronova - Postgraduate Student, Diagnostic Radiology Department No. 2, Kuban State Medical University; Radiologist, Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1.
Krasnodar
References
1. Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol. 2006;17(3):372–379. PMID: 16291774. https://doi.org/10.1093/annonc/mdj057
2. Dhamija E, Meena P, Ramalingam V, Sahoo R, Rastogi S, Thulkar S. Chemotherapy-induced pulmonary complications in cancer: significance of clinicoradiological correlation. Indian J Radiol Imaging. 2020;30(1):20–26. PMID: 32476746. PMCID: PMC7240883. https://doi.org/10.4103/ijri.IJRI_178_19
3. Nishino M, Hatabu H, Sholl LM, Ramaiya NH. Thoracic complications of precision cancer therapies: a practical guide for radiologists in the new era of cancer care. Radiographics. 2017;37(5):1371–1387. PMID: 28898185. PMCID: PMC5621730. https://doi.org/10.1148/rg.2017170015
4. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–2017. Published correction appears in N Engl J Med. 2018;379(22):2185. PMID: 25891304. PMCID: PMC5744258. https://doi.org/10.1056/NEJMoa1414428
5. Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607–1616. PMID: 27540850. https://doi.org/10.1001/jamaoncol.2016.2453
6. Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22(24):6051– 6060. PMID: 27535979. PMCID: PMC5161686. https://doi.org/10.1158/1078-0432.CCR-16-1320
7. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073–4126. Published correction appears in J Clin Oncol. 2022;40(3):315. PMID: 34724392. https://doi.org/10.1200/JCO.21.01440
8. Johkoh T, Lee KS, Nishino M, et al. Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society. Radiology. 2021;298(3):550–566. PMID: 33434111. https://doi.org/10.1148/radiol.2021203427
9. Tirumani SH, Ramaiya NH, Keraliya A, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3(10):1185–1192. PMID: 26100356. PMCID: PMC4596761. https://doi.org/10.1158/2326-6066.CIR-15-0102
10. Jitawatanarat P, Wee W. Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib. J Gastrointest Oncol. 2013;4(2):231–238. PMID: 23730520. PMCID: PMC3635194. https://doi.org/10.3978/j.issn.2078-6891.2013.008
11. Souza FF, Smith A, Araujo C, et al. New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know. Cancer Imaging. 2014;14(1):26. PMID: 25608887. PMCID: PMC4331831. https://doi.org/10.1186/1470-7330-14-26
12. Nakamura T, Matsumine A, Kawai A, et al. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study. Cancer. 2016;122(9):1408–1416. PMID: 26970174. PMCID: PMC5069581. https://doi.org/10.1002/cncr.29961
13. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531–2541. PMID: 16775234. https://doi.org/10.1056/NEJMoa055229
14. Diederich S. Chest CT for suspected pulmonary complications of oncologic therapies: how I review and report. Cancer Imaging. 2016;16:7. PMID: 27067027. PMCID: PMC4828781. https://doi.org/10.1186/s40644-016-0066-4
Review
For citations:
Zyablova E.I., Krivitskaya E.Yu., Voronova I.G. Pulmonary Complications of Cancer Therapy. Innovative Medicine of Kuban. 2024;(4):136-144. (In Russ.) https://doi.org/10.35401/2541-9897-2024-9-4-136-144
Views:
210
Email this article 
